Arterial Ischemic Stroke Clinical Trial
— KID-CLOTOfficial title:
National Retrospective Study Of Recanalization Treatments In Pediatric Arterial Ischemic Stroke (Intra-venous Thrombolysis and/or Endovascular Treatment: Thrombectomy, Intra-arterial Thrombolysis)
NCT number | NCT03887143 |
Other study ID # | NI18025HLJ |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | April 4, 2019 |
Est. completion date | May 29, 2021 |
Verified date | November 2021 |
Source | Assistance Publique - Hôpitaux de Paris |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The purpose of this study is to evaluate recanalization treatments use, safety and efficacy at the acute phase of arterial ischemic stroke in pediatric patients
Status | Completed |
Enrollment | 70 |
Est. completion date | May 29, 2021 |
Est. primary completion date | May 29, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A to 18 Years |
Eligibility | Inclusion Criteria: - Patients under 18 years old - Suspected or confirmed cerebral infarction - With recanalization treatment in the acute phase : intravenous thrombolysis +/- intra-arterial thrombolysis +/- thrombectomy - Patients treated between the January 2015, 1st and the May 2018, 31st - Collection of non-opposition from legal representatives Exclusion Criteria: - Refusal of the patient's legal representative to participate in the study |
Country | Name | City | State |
---|---|---|---|
France | Necker- Enfants Malades Hospital | Paris |
Lead Sponsor | Collaborator |
---|---|
Assistance Publique - Hôpitaux de Paris |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Acute management of stroke: | Median time from symptom onset to Imaging (minutes) | 1 day | |
Primary | Acute management of stroke: | Median time from symptom onset to beginning of recanalization treatment (minutes) | 1 day | |
Primary | Acute management of stroke: | Median door-to-needle delay (minutes) | 1 day | |
Secondary | Treatment-emergent adverse events: | Intracranial hemorrhage (yes/no) | 7 days | |
Secondary | Treatment-emergent adverse events: | clinically symptomatic (yes/no) | 7 days | |
Secondary | Treatment-emergent adverse events: | Peripheral hemorrhage (yes/no) | 7 days | |
Secondary | factors potentially associated with clinical outcome: univariate and multivariate analysis, step by step analysis | age of onset (year, months) | 12 months | |
Secondary | factors potentially associated with clinical outcome: univariate and multivariate analysis, step by step analysis | Mechanism of stroke (CASCADE classification) | 12 months | |
Secondary | factors potentially associated with clinical outcome: univariate and multivariate analysis, step by step analysis | stroke location (name of artery territory) | 12 months | |
Secondary | factors potentially associated with clinical outcome: univariate and multivariate analysis, step by step analysis | time from symptom onset to beginning of recanalization treatment (minutes) | 12 months | |
Secondary | factors potentially associated with clinical outcome: univariate and multivariate analysis, step by step analysis | initial imagine ASPECT Alberta Stroke Program Early CT Score. score (units on an scale). The ASPECTS score is a 10-point quantitative topographic CT scan score used in patients with middle cerebral artery (MCA) stroke. I has also been adapted to be used with MR scans.
All scale ranges : Segmental assessment of the MCA vascular territory is made and 1 point is deducted from the initial score of 10 for every region involved (caudate, putamen, internal capsule, nsular cortex, M1(anterior MCA cortex=frontal operculum), M2(MCA cortex lateral to insular ribbon=anterior temporal lobe), M3(posterior MCA cortex=posterior temporal lobe, M4(anterior MCA territory immediately superior to M1), M5(lateral MCA territory immediately superior to M2), M6(posterior MCA territory immediately superior to M3) For each scale, values better or worse : In adults, an ASPECTS score less than or equal to 7 predicts a worse functional outcome at 3 months as well as symptomatic hemorrhage |
12 months | |
Secondary | factors potentially associated with clinical outcome: univariate and multivariate analysis, step by step analysis | Association with :Modified Rankin Scale - mRS (Units on a scale)The mRS is a 6-point quantitative measure of functional independence.
All scale ranges: 0=No symptoms at all No significant disability despite symptoms; able to carry out all usual duties and activities Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance disability; requiring some help, but able to walk without assistance Moderate Moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance Severe disability; bedridden, incontinent and requiring constant nursing care and attention Dead For each scales range, values better or worse : In the literature, good outcome is usually considered for patients with mRS [0-2]. Very good outcome is considered for patients with mRS [0-1]. We will use the same thresholds |
12 months | |
Secondary | factors potentially associated with clinical outcome: univariate and multivariate analysis, step by step analysis | Association with :
- The Pediatric Stroke Outcome Measure - PSOM (Units on a scale) =scale has been designed and published to quantify functional consequences of stroke in children. The PSOM is a detailed neurological examination, with outcome scored in terms of degree of impairment in each of language, cognition, and sensorimotor. We wil use the PSOM-SNE version (PSOM-Short Neuro Exam version). All scale ranges (0-0,5-1 or 2): - Sensorimotor deficit, Language Deficit - Production, Language Deficit - Comprehension, Cognitive or Behavioural Deficit. Total score on 10 For each scale range, values better or worse: Total impairment scores (out of a maximum of 10) will be considered as previously published, i.e. total score 0 or 0.5 representing good outcome, and poor outcome =1. All subscales ranges (Normal, Anormal, Not Done): Level of consciousness, Behaviour, mental status, Language, Cranial nerves, Motor testing, Tendon reflexes, Fine motor coordination, Sensory, Gate |
12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT03249844 -
Paediatric Arteriopathy Steroid Aspirin Project
|
Phase 3 | |
Enrolling by invitation |
NCT06040255 -
Focal Cerebral Arteriopathy Steroid Trial
|
Phase 4 | |
Completed |
NCT04962503 -
A Proof of Concept Study to Evaluate the Safety of Afamelanotide in Patients With Acute Arterial Ischaemic Stroke (AIS)
|
Phase 2 |